Hepatocellular carcinoma (HCC) occurs at a rate of 3–5% per year in patients with compensated cirrhosis, and it often represents the first disease complication and the main cause of death in these patients (1). Surveillance for HCC is recommended by all liver disease associations, as it increases patient survival mainly as a result of early diagnosis of the tumour, allowing most patients to convey to curative treatments (2,3)
Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein / 23. E.G. Giannini, F. Trevisani. - In: HEPATOBILIARY SURGERY AND NUTRITION. - ISSN 2304-3881. - STAMPA. - 8:(2019), pp. 515-518. [10.21037/hbsn.2019.04.19]
Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein
F. Trevisani
2019
Abstract
Hepatocellular carcinoma (HCC) occurs at a rate of 3–5% per year in patients with compensated cirrhosis, and it often represents the first disease complication and the main cause of death in these patients (1). Surveillance for HCC is recommended by all liver disease associations, as it increases patient survival mainly as a result of early diagnosis of the tumour, allowing most patients to convey to curative treatments (2,3)I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
